Skip to main content
Figure 2 | Genetic Vaccines and Therapy

Figure 2

From: Combined vascular endothelial growth factor-A and fibroblast growth factor 4 gene transfer improves wound healing in diabetic mice

Figure 2

AAV-VEGF-A and AAV-FGF4-IRES-VEGF-A accelerates time to wound closure in db/db mice. (A) Quantification of the wound area at consecutive days. Reduction of the wound area after AAV-VEGF-A injection was significantly enhanced starting from day 17. At day 19 all wounds in AAV-VEGF-A group were covered with epithelium and considered closed (arrow, inset). The reduction of the wound area after AAV-FGF4-IRES-VEGF-A injection was even more visible when compared to AAV-LacZ-injected controls starting already from day 13. At day 17 all wounds in AAV-FGF4-IRES-VEGF-A group were covered with epithelium and considered closed (arrow, inset). No acceleration of the wound closure was observed after AAV-FGF4-IRES-GFP at any time-point and the last wounds in this group were considered closed at day 21 together with PBS- and AAV-LacZ-injected animals. (B) Representative pictures taken at day 19 showing wounds of AAV-VEGF-A and AAV-FGF4-IRES-VEGF-A-injected animals completely covered with epithelium and prolonged healing process in PBS-, AAV-LacZ- and AAV-FGF4-IRES-GFP-treated mice. Graph represents means ± SEM (n = 10 wounds/group); *p < 0.05 vs PBS and AAV-LacZ.

Back to article page

Genetic Vaccines and Therapy

ISSN: 1479-0556